An educational video to increase clinical trials enrollment among breast cancer patientsWEI DU; MOOD, Darlene; GADGEEL, Shirish et al.Breast cancer research and treatment. 2009, Vol 117, Num 2, pp 339-347, issn 0167-6806, 9 p.Article

Predictors of enrollment in lung cancer clinical trialsWEI DU; GADGEEL, Shirish M; SIMON, Michael S et al.Cancer. 2006, Vol 106, Num 2, pp 420-425, issn 0008-543X, 6 p.Article

Retrospective review of cancer patients ≥80 years old treated with chemotherapy at a comprehensive cancer centerCHOI, Minsig; JIANG, Peter Q; HEILBRUN, Lance K et al.Critical reviews in oncology/hematology. 2008, Vol 67, Num 3, pp 268-272, issn 1040-8428, 5 p.Article

The Natural Tumor Suppressor Protein Maspin and Potential Application in Non Small Cell Lung Cancer : Pharmaceutical Design of Novel Anticancer Agents: A Lesson from NatureLONARDO, Fulvio; XIAOHUA LI; KAPLUN, Alexander et al.Current pharmaceutical design (Print). 2010, Vol 16, Num 16, pp 1877-1881, issn 1381-6128, 5 p.Article

Patterns of Care in a Population-based Sample of Soft Tissue Sarcoma Patients in the United StatesGADGEEL, Shirish M; HARLAN, Linda C; ZERUTO, Christopher A et al.Cancer. 2009, Vol 115, Num 12, pp 2744-2754, issn 0008-543X, 11 p.Article

Biochemotherapy of melanomaFLAHERTY, Lawrence E; GADGEEL, Shirish M.Seminars in oncology. 2002, Vol 29, Num 5, pp 446-455, issn 0093-7754Article

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancerHEYMACH, John V; JOHNSON, Bruce E; KENNEDY, Sarah J et al.Journal of clinical oncology. 2007, Vol 25, Num 27, pp 4270-4277, issn 0732-183X, 8 p.Article

Impact of race in lung cancer : Analysis of temporal trends from a Surveillance, Epidemiology, and End Results databaseGADGEEL, Shirish M; SEVERSON, Richard K; YING KAU et al.Chest. 2001, Vol 120, Num 1, pp 55-63, issn 0012-3692Article

Phase I study of bryostatin 1 and gemcitabineEL-RAYES, Basil F; GADGEEL, Shirish; SHIELDS, Anthony F et al.Clinical cancer research. 2006, Vol 12, Num 23, pp 7059-7062, issn 1078-0432, 4 p.Article

Phase I and Pharmacokinetic Study of Lapatinib and Docetaxel in Patients With Advanced CancerLORUSSO, Patricia M; JONES, Suzanne F; KOCH, Kevin M et al.Journal of clinical oncology. 2008, Vol 26, Num 18, pp 3051-3056, issn 0732-183X, 6 p.Article

A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapyRIELY, Gregory J; GADGEEL, Shirish; ROTHMAN, Ivan et al.Lung cancer. 2007, Vol 55, Num 2, pp 181-185, issn 0169-5002, 5 p.Article

Randomized International Phase III Trial of ERCC1 and RRM1 Expression―Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non―Small-Cell Lung CancerBEPLER, Gerold; WILLIAMS, Charles; CHIAPPORI, Alberto et al.Journal of clinical oncology. 2013, Vol 31, Num 19, pp 2404-2412, issn 0732-183X, 9 p.Article

Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528GADGEEL, Shirish M; LEW, Danika L; SYNOLD, Timothy W et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 5, pp 1089-1096, issn 0344-5704, 8 p.Article

Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung CancerALLEN, Jeffrey W; MOON, James; REDMAN, Mary et al.Journal of clinical oncology. 2014, Vol 32, Num 23, pp 2463-2470, issn 0732-183X, 8 p.Article

A Phase 2 Trial of Dacomitinib (PF-00299804), an Oral, Irreversible Pan-HER (Human Epidermal Growth Factor Receptor) Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer After Failure of Prior Chemotherapy and ErlotinibRECKAMP, Karen L; GIACCONE, Giuseppe; RUIZ-GARCIA, Ana et al.Cancer. 2014, Vol 120, Num 8, pp 1145-1154, issn 0008-543X, 10 p.Article